The FDA recently halted a clinical trial evaluating an investigational stem cell-derived therapy for people with type 1 diabetes with impaired hypoglycemia awareness and severe hypoglycemia.
The clinical hold on VX-880 (Vertex Pharmaceuticals) was due to insufficient data to support dose escalation, according to an industry press release. It was the top story in endocrinology last week.
Another top story covered study data that showed adolescent boys who are exposed to higher levels of two types of endocrine-disrupting chemicals, per- and polyfluoroalkyl substances and phthalates, may have